Literature DB >> 2008651

The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia.

E Cersosimo1, P W Pisters, G Pesola, A Rogatko, N A Vydelingum, D Bajorunas, M F Brennan.   

Abstract

With the euglycemic clamp technique, we evaluated the effects of graded doses of insulin on glucose turnover rates and forearm lactate balance in five weight-losing patients with cancer before surgery and five age- and weight-matched healthy volunteers (control subjects). Insulin was infused sequentially at increasing rates of 0.5 (low physiologic), 1.0 (high physiologic), and 4.0 (supraphysiologic) mU/kg.min for 120 minutes each. Concurrently, rates of glucose appearance and disappearance were derived from [3-3H] glucose infusion. The mean postabsorptive rate of glucose appearance in patients (2.9 +/- 0.1 mg/kg.min) was significantly higher (p less than 0.02) than that of control subjects (1.98 +/- 0.16 mg/kg.min). Complete suppression of endogenous glucose production occurred at high physiologic insulin concentrations. With progressive insulin infusion, the rate of glucose disappearance increased to 3.6 +/- 1.2, 8.7 +/- 0.8, and 13.7 +/- 1.1 mg/kg/min in control subjects and 2.9 +/- 0.4, 5.3 +/- 0.3, and 10.9 +/- 0.9 mg/kg.min in patients, significantly different from that of control subjects (p less than 0.05) during the intermediate (high physiologic) insulin infusion. A comparable slight increase in arterial plasma lactate concentration was observed in both groups with progressive hyperinsulinemia. Baseline peripheral lactate flux was identical in patients (-272 +/- 56 nmol/100 gm.min) and in controls (-271 +/- 57 nmol/100 gm.min). Progressive physiologic hyperinsulinemia resulted in significantly (p less than 0.05) augmented peripheral lactate efflux in patients (-824 +/- 181 nmol/100 gm.min) compared with control subjects (-287 +/- 64 nmol/100 gm.min). Supraphysiologic insulin abolished this increased lactate efflux in patients. Postabsorptive rates of endogenous glucose appearance in weight-losing patients with cancer were elevated, but complete suppression was achieved with insulin concentrations in the physiologic range. Total body glucose use was diminished in these patients, consistent with a state of insulin resistance. This impaired insulin action on peripheral glucose use was associated with an increase in peripheral lactate release in patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2008651

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia.

Authors:  Michelle L Asp; Min Tian; Kara L Kliewer; Martha A Belury
Journal:  Cancer Biol Ther       Date:  2011-12-01       Impact factor: 4.742

2.  Impaired glucose tolerance in healthy men with low body weight.

Authors:  Kamila Jauch-Chara; André Schmoller; Kerstin M Oltmanns
Journal:  Nutr J       Date:  2011-02-07       Impact factor: 3.271

3.  Effects of insulin and insulin-like growth factors on protein and energy metabolism in tumour-bearing rats.

Authors:  F M Tomas; C S Chandler; P Coyle; C S Bourgeois; J L Burgoyne; A M Rofe
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

4.  Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.

Authors:  R C Eastman; R E Carson; D G Orloff; C S Cochran; J F Perdue; M M Rechler; F Lanau; C T Roberts; J Shapiro; J Roth
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chavez-Blanco; Guadalupe Dominguez-Gomez; Mandy Juarez; Ariana Vargas-Castillo; Rafael Isaac Ponce-Toledo; Donna Lai; Sheng Hua; Armando R Tovar; Nimbe Torres; Delia Perez-Montiel; Jose Diaz-Chavez; Alfonso Duenas-Gonzalez
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.